{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:43Z","timestamp":1792788343368,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Santa Clara University College of Arts and Sciences","id":[{"id":"https:\/\/ror.org\/03ypqe447","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-026-07930-3","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:45:22Z","timestamp":1782740722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticancer proteasome inhibitors are detrimental to the growth of Toxoplasma gondii in vitro"],"prefix":"10.1186","volume":"19","author":[{"given":"Meir","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale S.","family":"Guiton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"7930_CR1","unstructured":"Molan A, Nosaka K, Hunter M, Wang W. Global status of Toxoplasma gondii infection: systematic review and prevalence snapshots. Trop Biomed . 2019;36(4):898-925."},{"key":"7930_CR2","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/S2352-3018(17)30005-X","volume":"4","author":"Z-D Wang","year":"2017","unstructured":"Wang Z-D, Wang S-C, Liu H-H, Ma H-Y, Li Z-Y, Wei F, et al. Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis. Lancet HIV. 2017;4:e177\u201388. https:\/\/doi.org\/10.1016\/S2352-3018(17)30005-X.","journal-title":"Lancet HIV"},{"key":"7930_CR3","doi-asserted-by":"publisher","first-page":"894573","DOI":"10.3389\/fped.2022.894573","volume":"10","author":"L Bollani","year":"2022","unstructured":"Bollani L, Auriti C, Achille C, Garofoli F, De Rose DU, Meroni V, et al. Congenital Toxoplasmosis: The State of the Art. Front Pediatr. 2022;10:894573. https:\/\/doi.org\/10.3389\/fped.2022.894573.","journal-title":"Front Pediatr"},{"key":"7930_CR4","doi-asserted-by":"publisher","unstructured":"Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis Off Publ Infect Dis Soc Am. 1992;15:211\u201322. https:\/\/doi.org\/10.1093\/clinids\/15.2.211","DOI":"10.1093\/clinids\/15.2.211"},{"key":"7930_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/microorganisms9122531","volume":"9","author":"RE Hajj","year":"2021","unstructured":"Hajj RE, Tawk L, Itani S, Hamie M, Ezzeddine J, Sabban ME, et al. Toxoplasmosis: Current and Emerging Parasite Druggable Targets. Microorganisms. 2021;9:2531. https:\/\/doi.org\/10.3390\/microorganisms9122531.","journal-title":"Microorganisms"},{"key":"7930_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","volume":"17","author":"RR Ben-Harari","year":"2017","unstructured":"Ben-Harari RR, Goodwin E, Casoy J. Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review. Drugs RD. 2017;17:523. https:\/\/doi.org\/10.1007\/s40268-017-0206-8.","journal-title":"Drugs RD"},{"key":"7930_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41598-020-80569-7","volume":"11","author":"AM Shammaa","year":"2021","unstructured":"Shammaa AM, Powell TG, Benmerzouga I. Adverse outcomes associated with the treatment of Toxoplasma infections. Sci Rep. 2021;11:1035. https:\/\/doi.org\/10.1038\/s41598-020-80569-7.","journal-title":"Sci Rep"},{"key":"7930_CR8","doi-asserted-by":"publisher","unstructured":"The proteasome. A supramolecular assembly designed for controlled proteolysis. Adv Protein Chem 2001. https:\/\/doi.org\/10.1016\/S0065-3233(01)59006-3.","DOI":"10.1016\/S0065-3233(01)59006-3"},{"key":"7930_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/14728222.2019.1685981","volume":"23","author":"SC Xie","year":"2019","unstructured":"Xie SC, Dick LR, Gould A, Brand S, Tilley L. The proteasome as a target for protozoan parasites. Expert Opin Ther Targets. 2019;23:903\u201314. https:\/\/doi.org\/10.1080\/14728222.2019.1685981.","journal-title":"Expert Opin Ther Targets"},{"key":"7930_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature19339","volume":"537","author":"S Khare","year":"2016","unstructured":"Khare S, Nagle AS, Biggart A, Lai YH, Liang F, Davis LC, et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature. 2016;537:229\u201333. https:\/\/doi.org\/10.1038\/nature19339.","journal-title":"Nature"},{"key":"7930_CR11","doi-asserted-by":"publisher","first-page":"e1002132","DOI":"10.1371\/journal.pbio.1002132","volume":"13","author":"C Dogovski","year":"2015","unstructured":"Dogovski C, Xie SC, Burgio G, Bridgford J, Mok S, McCaw JM, et al. Targeting the Cell Stress Response of Plasmodium falciparum to Overcome Artemisinin Resistance. PLOS Biol. 2015;13:e1002132. https:\/\/doi.org\/10.1371\/journal.pbio.1002132.","journal-title":"PLOS Biol"},{"key":"7930_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nature16936","volume":"530","author":"H Li","year":"2016","unstructured":"Li H, O\u2019Donoghue AJ, van der Linden WA, Xie SC, Yoo E, Foe IT, et al. Structure- and function-based design of Plasmodium-selective proteasome inhibitors. Nature. 2016;530:233\u20136. https:\/\/doi.org\/10.1038\/nature16936.","journal-title":"Nature"},{"key":"7930_CR13","doi-asserted-by":"publisher","first-page":"E6863","DOI":"10.1073\/pnas.1806109115","volume":"115","author":"LA Kirkman","year":"2018","unstructured":"Kirkman LA, Zhan W, Visone J, Dziedziech A, Singh PK, Fan H, et al. Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. Proc Natl Acad Sci. 2018;115:E6863\u201370. https:\/\/doi.org\/10.1073\/pnas.1806109115.","journal-title":"Proc Natl Acad Sci"},{"key":"7930_CR14","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41564-019-0524-4","volume":"4","author":"SC Xie","year":"2019","unstructured":"Xie SC, Metcalfe RD, Hanssen E, Yang T, Gillett DL, Leis AP, et al. The structure of the PA28-20S proteasome complex from Plasmodium falciparum and implications for proteostasis. Nat Microbiol. 2019;4:1990\u20132000. https:\/\/doi.org\/10.1038\/s41564-019-0524-4.","journal-title":"Nat Microbiol"},{"key":"7930_CR15","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071\u20136.","journal-title":"Cancer Res"},{"issue":"Pt 1","key":"7930_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1017\/s0031182099006071","volume":"121","author":"MK Shaw","year":"2000","unstructured":"Shaw MK, He CY, Roos DS, Tilney LG. Proteasome inhibitors block intracellular growth and replication of Toxoplasma gondii. Parasitology. 2000;121(Pt 1):35\u201347. https:\/\/doi.org\/10.1017\/s0031182099006071.","journal-title":"Parasitology"},{"key":"7930_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00436-002-0644-1","volume":"88","author":"A Paugam","year":"2002","unstructured":"Paugam A, Creuzet C, Dupouy-Camet J, Roisin P. In vitro effects of gliotoxin, a natural proteasome inhibitor, on the infectivity and proteolytic activity of Toxoplasma gondii. Parasitol Res. 2002;88:785\u20137. https:\/\/doi.org\/10.1007\/s00436-002-0644-1.","journal-title":"Parasitol Res"},{"key":"7930_CR18","doi-asserted-by":"publisher","unstructured":"Chen Q-W, Dong K, Qin H-X, Yang Y-K, He J-L, Li J, et al. Direct and indirect inhibition effects of resveratrol against Toxoplasma gondii tachyzoites In Vitro. Antimicrob Agent Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.01233-18.","DOI":"10.1128\/aac.01233-18"},{"key":"7930_CR19","first-page":"369","volume":"92","author":"OS Adeyemi","year":"2019","unstructured":"Adeyemi OS, Atolani O, Awakan OJ, Olaolu TD, Nwonuma CO, Alejolowo O, et al. In Vitro Screening to Identify Anti-Toxoplasma Compounds and In Silico Modeling for Bioactivities and Toxicity. Yale J Biol Med. 2019;92:369\u201383.","journal-title":"Yale J Biol Med"},{"key":"7930_CR20","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome. Cancer Res. 2007;67:6383\u201391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4086.","journal-title":"Cancer Res"},{"key":"7930_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 2014;15:1503\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(14)71125-8.","journal-title":"Lancet Oncol"},{"key":"7930_CR22","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.chembiol.2012.09.019","volume":"19","author":"H Li","year":"2012","unstructured":"Li H, Ponder EL, Verdoes M, Asbjornsdottir KH, Deu E, Edgington LE, et al. Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol. 2012;19:1535\u201345. https:\/\/doi.org\/10.1016\/j.chembiol.2012.09.019.","journal-title":"Chem Biol"},{"key":"7930_CR23","doi-asserted-by":"publisher","first-page":"e13064","DOI":"10.1111\/jeu.13064","volume":"72","author":"T Aderanti","year":"2025","unstructured":"Aderanti T, Marshall JM, Thekkiniath J. Effect of protease inhibitors on the intraerythrocytic development of Babesia microti and Babesia duncani, the causative agents of human babesiosis. J Eukaryot Microbiol. 2025;72:e13064. https:\/\/doi.org\/10.1111\/jeu.13064.","journal-title":"J Eukaryot Microbiol"},{"key":"7930_CR24","doi-asserted-by":"publisher","first-page":"e0129165","DOI":"10.1371\/journal.pone.0129165","volume":"10","author":"A Pereira-Neves","year":"2015","unstructured":"Pereira-Neves A, Gonzaga L, Menna-Barreto RFS, Benchimol M. Characterisation of 20S Proteasome in Tritrichomonas foetus and Its Role during the Cell Cycle and Transformation into Endoflagellar Form. PLoS ONE. 2015;10:e0129165. https:\/\/doi.org\/10.1371\/journal.pone.0129165.","journal-title":"PLoS ONE"},{"key":"7930_CR25","doi-asserted-by":"publisher","unstructured":"O\u2019Donoghue AJ, Bibo-Verdugo B, Miyamoto Y, Wang SC, Yang JZ, Zuill DE, et al. 20S proteasome as a drug target in Trichomonas vaginalis. Antimicrob Agent Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.00448-19.","DOI":"10.1128\/aac.00448-19"},{"key":"7930_CR26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0092-8674(00)81071-5","volume":"84","author":"JM Dobrowolski","year":"1996","unstructured":"Dobrowolski JM, Sibley LD. Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. Cell. 1996;84:933\u20139. https:\/\/doi.org\/10.1016\/s0092-8674(00)81071-5.","journal-title":"Cell"},{"key":"7930_CR27","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1128\/AAC.00582-07","volume":"51","author":"K Nagamune","year":"2007","unstructured":"Nagamune K, Moreno SNJ, Sibley LD. Artemisinin-Resistant Mutants of Toxoplasma gondii Have Altered Calcium Homeostasis. Antimicrob Agents Chemother. 2007;51:3816\u201323. https:\/\/doi.org\/10.1128\/AAC.00582-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"7930_CR28","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/415926a","volume":"415","author":"BA Fox","year":"2002","unstructured":"Fox BA, Bzik DJ. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature. 2002;415:926\u20139. https:\/\/doi.org\/10.1038\/415926a.","journal-title":"Nature"},{"key":"7930_CR29","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/pharmaceutics14081634","volume":"14","author":"DC Cajazeiro","year":"2022","unstructured":"Cajazeiro DC, Toledo PPM, de Sousa NF, Scotti MT, Reim\u00e3o JQ. Drug Repurposing Based on Protozoan Proteome: In Vitro Evaluation of In Silico Screened Compounds against Toxoplasma gondii. Pharmaceutics. 2022;14:1634. https:\/\/doi.org\/10.3390\/pharmaceutics14081634.","journal-title":"Pharmaceutics"},{"key":"7930_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","volume":"169","author":"GA Collins","year":"2017","unstructured":"Collins GA, Goldberg AL. The Logic of the 26S Proteasome. Cell. 2017;169:792\u2013806. https:\/\/doi.org\/10.1016\/j.cell.2017.04.023.","journal-title":"Cell"},{"key":"7930_CR31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","volume":"87","author":"JAM Bard","year":"2018","unstructured":"Bard JAM, Goodall EA, Greene ER, Jonsson E, Dong KC, Martin A. Structure and Function of the 26S Proteasome. Annu Rev Biochem. 2018;87:697\u2013724. https:\/\/doi.org\/10.1146\/annurev-biochem-062917-011931.","journal-title":"Annu Rev Biochem"},{"key":"7930_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","volume":"19","author":"AF Kisselev","year":"2012","unstructured":"Kisselev AF, van der Linden WA, Overkleeft HS. Proteasome Inhibitors: An Expanding Army Attacking a Unique Target. Chem Biol. 2012;19:99\u2013115. https:\/\/doi.org\/10.1016\/j.chembiol.2012.01.003.","journal-title":"Chem Biol"},{"key":"7930_CR33","doi-asserted-by":"publisher","first-page":"123125","DOI":"10.1016\/j.lfs.2024.123125","volume":"358","author":"Bortezomib in cancer therapy","year":"2024","unstructured":"Bortezomib in cancer therapy. Mechanisms, side effects, and future proteasome inhibitors. Life Sci. 2024;358:123125. https:\/\/doi.org\/10.1016\/j.lfs.2024.123125.","journal-title":"Life Sci"},{"key":"7930_CR34","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, et al. Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer. Cancer Res. 2010;70:1970\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2766.","journal-title":"Cancer Res"},{"key":"7930_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4939-9857-9_2","volume":"2071","author":"OS Harb","year":"2020","unstructured":"Harb OS, Roos DS. ToxoDB: Functional Genomics Resource for Toxoplasma and Related Organisms. Methods Mol Biol Clifton NJ. 2020;2071:27\u201347. https:\/\/doi.org\/10.1007\/978-1-4939-9857-9_2.","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"7930_CR36","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.cell.2016.08.019","volume":"166","author":"SM Sidik","year":"2016","unstructured":"Sidik SM, Huet D, Ganesan SM, Huynh M-H, Wang T, Nasamu AS, et al. A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Cell. 2016;166:1423\u2013e143512. https:\/\/doi.org\/10.1016\/j.cell.2016.08.019.","journal-title":"Cell"},{"key":"7930_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1051\/parasite\/2001084267","volume":"8","author":"A Paugam","year":"2001","unstructured":"Paugam A, Creuzet C, Dupouy-Camet J, Roisin MP. Evidence for the existence of a proteasome in Toxoplasma gondii: intracellular localization and specific peptidase activities. Parasite. 2001;8:267\u201373. https:\/\/doi.org\/10.1051\/parasite\/2001084267.","journal-title":"Parasite"},{"key":"7930_CR38","doi-asserted-by":"publisher","first-page":"134290","DOI":"10.1016\/j.ijbiomac.2024.134290","volume":"277","author":"Structural analysis and shape","year":"2024","unstructured":"Structural analysis and shape-. based identification of novel inhibitors targeting the Trypanosoma cruzi proteasome. Int J Biol Macromol. 2024;277:134290. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.134290.","journal-title":"Int J Biol Macromol"},{"key":"7930_CR39","doi-asserted-by":"publisher","first-page":"108049","DOI":"10.1016\/j.jbc.2024.108049","volume":"301","author":"TC Eadsforth","year":"2025","unstructured":"Eadsforth TC, Torrie LS, Rowland P, Edgar EV, MacLean LM, Paterson C, et al. Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitors. J Biol Chem. 2025;301:108049. https:\/\/doi.org\/10.1016\/j.jbc.2024.108049.","journal-title":"J Biol Chem"},{"key":"7930_CR40","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1111\/febs.13780","volume":"283","author":"H Li","year":"2016","unstructured":"Li H, Bogyo M, da Fonseca PCA. The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria. FEBS J. 2016;283:4238\u201343. https:\/\/doi.org\/10.1111\/febs.13780.","journal-title":"FEBS J"},{"key":"7930_CR41","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.1002\/anie.202015845","volume":"60","author":"W Zhan","year":"2021","unstructured":"Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, et al. Development of a highly selective Plasmodium falciparum proteasome inhibitor with anti-malaria activity in humanized mice. Angew Chem Int Ed Engl. 2021;60:9279\u201383. https:\/\/doi.org\/10.1002\/anie.202015845.","journal-title":"Angew Chem Int Ed Engl"},{"key":"7930_CR42","doi-asserted-by":"publisher","first-page":"11881","DOI":"10.3390\/ijms252211881","volume":"25","author":"M Yasir","year":"2024","unstructured":"Yasir M, Park J, Han E-T, Han J-H, Park WS, Chun W. Identification of Malaria-Selective Proteasome \u03b25 Inhibitors Through Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation. Int J Mol Sci. 2024;25:11881. https:\/\/doi.org\/10.3390\/ijms252211881.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-026-07930-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07930-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07930-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:08:55Z","timestamp":1789517335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-026-07930-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7930"],"URL":"https:\/\/doi.org\/10.1186\/s13104-026-07930-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8962776\/v1","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"352"}}